AGN-241751
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | NMDA receptor modulator |
| Identifiers | |
| CAS Number | |
AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD).[1][2] It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018.[1][2] Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD.[3][4][5] Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel.[2][6] As of May 2018, the drug is in phase I clinical trials.[1][2]
See also[]
References[]
- ^ a b c "Research programme: NMDA receptor modulators - Allergan - AdisInsight". adisinsight.springer.com.
- ^ a b c d Inc., Aptinyx. "Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration". www.prnewswire.com.
- ^ Vazquez GH, Camino S, Tondo L, Baldessarini RJ (2018). "Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics". CNS Neurol Disord Drug Targets. 16 (8): 858–869. doi:10.2174/1871527316666170728165648. PMID 28758582.
- ^ "Rapastinel - Allergan - AdisInsight". adisinsight.springer.com.
- ^ "Apimostinel - Allergan - AdisInsight". adisinsight.springer.com.
- ^ "J&J therapy for suicidal depressives 'a breakthrough', says FDA". PMLive. 17 August 2016.
External links[]
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by . |
Categories:
- Antidepressants
- Drugs with undisclosed chemical structures
- Experimental drugs
- NMDA receptor modulators
- Nervous system drug stubs